Comparative studies to evaluate relative in vitro potency of luteolin in inducing cell cycle arrest and apoptosis in HaCat and A375 cells

Asian Pacific Journal of Cancer Prevention

Volumn 14, Issue 2, 2013, Pages 631-637

  George, Vazhapilly Cijo ^a   Kumar, Devanga Ragupathi Naveen ^a   Suresh, Palamadai Krishnan ^a   Kumar, Sanjay ^b   Kumar, Rangasamy Ashok ^c  

^a VIT UNIVERSITY   (India)

^b CHRISTIAN MEDICAL COLLEGE   (India)

^c GOVERNMENT ARTS COLLEGE   (India)

Author keywords

Apoptosis; Cell cycle; Cytotoxicity; Luteolin; Skin cancer

Indexed keywords

1,1 DIPHENYL 2 PICRYLHYDRAZYL; 2,2-DIPHENYL-1-PICRYLHYDRAZYL; BIPHENYL DERIVATIVE; FREE RADICAL; IRON; LUTEOLIN; PICRIC ACID; SCAVENGER;

APOPTOSIS; ARTICLE; CELL PROLIFERATION; CELL SURVIVAL; CHEMISTRY; DNA FRAGMENTATION; DRUG EFFECT; G1 PHASE CELL CYCLE CHECKPOINT; HUMAN; KERATINOCYTE; M PHASE CELL CYCLE CHECKPOINT; MELANOMA; SKIN TUMOR; TUMOR CELL LINE;

APOPTOSIS; BIPHENYL COMPOUNDS; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; DNA FRAGMENTATION; FREE RADICAL SCAVENGERS; FREE RADICALS; G1 PHASE CELL CYCLE CHECKPOINTS; HUMANS; IRON; KERATINOCYTES; LUTEOLIN; M PHASE CELL CYCLE CHECKPOINTS; MELANOMA; PICRATES; SKIN NEOPLASMS;

EID: 84877671041     PISSN: 15137368     EISSN: 2476762X     Source Type: Journal    
DOI: 10.7314/APJCP.2013.14.2.631     Document Type: Article

References (49)

1. Adinarayan M, Krishnamurthy SP. (2011). Clinicopathological evaluation of nonmelanoma skin cancer. Indian J Dermatol, 56, 670-2.
2. Benzie IF, Strain JJ. (1996). The ferric reducing ability of plasma (FRAP) as a measure of "antioxidant power": the FRAP assay. Anal Biochem, 239, 70-6.
3. Brady MS, Kaushal A, KO C, et al. (2011). Melanoma and other skin cancers. Cancer Management, 14, 1-32.
4. Chahar KM, Sharma N, Dobhal MP, et al. (2011). Flavonoids: a versatile source of anticancer drugs. Pharmacognosy Rev, 5, 1-12.
5. Chang J, Hsu Y, Kuo P, et al. (2005). Increase of Bax/Bcl-XL ratio and arrest of cell cycle by luteolin in immortalized human hepatoma cell line. Life Sci, 76, 1883-93.
6. Chen T, Wong YS. (2009). Selenocystine induces reactive oxygen species mediated apoptosis in human cancer cells. Biomed Pharmacother, 63, 105-13.
7. Chiang CT, Way TD, Lin JK. (2007). Sensitizing HER2-overexpressing cancer cells to luteolin-induced apoptosis through suppressing p21(WAF1/CIP1) expression with rapamycin. Mol Cancer Ther, 6, 2127-38.
8. Chung H, Suh EK, Han IO, et al. (2011). Keratinocytederived laminin-332 promotes adhesion and migration in melanocytes and melanoma. J Biol Chem, 15, 13438-47.
9. Deorukhkar A, Krishnan S, Sethi G. (2007). Back to basics: how natural products can provide the basis for new therapeutics. Expert Opin Investig Drugs, 16, 1753-73.
10. Dua P, Gude RP. (2006). Antiproliferative and antiproteolytic activity of pentoxifylline in cultures of B16F10 melanoma cells. Cancer Chemother Pharmacol, 58, 195-202.
11. Fabbrocini G, Triassi M, Mauriello MC, et al. (2010). Epidemiology of skin cancer: role of some environmental factors. Cancers, 2, 1980-9.
12. Fecker LF, Geilen CC, Hossini AM, et al. (2005). Selective induction of apoptosis in melanoma cells by tyrosinase promoter-controlled CD95 ligand overexpression. J Invest Dermatol, 124, 221-8.
13. Garbe C, Eigentler TK, Keilholz U, et al. (2011). Systematic review of medical treatment in melanoma: current status and future prospects. The Oncologist, 16, 5-24.
14. George VC, Kumar DRN, Rajkumar V, et al. (2012). Quantitative assessment of the relative antineoplastic potential of the n-butanolic leaf extract of Annona muricata Linn. in normal and immortalized human cell lines. Asian Pac J Cancer Prev, 13, 699-704.
15. Gibellini L, Pinti M, Nasi M, et al. (2010). Interfering with ROS metabolism in cancer cells: the potential role of quercetin. Cancers, 2, 1288-311.
16. Girschik J, Fritschi L, Threlfall T, et al. (2008). Deaths from nonmelanoma skin cancer in eastern Australia. Cancer Causes Control, 19, 879-85.
17. Green DR, Reed JC. (1998). Mitochondria and apoptosis. Science, 281, 1309-12.
18. Gu YH, Belury MA. (2005). Selective induction of apoptosis in murine skin carcinoma cells (CH72) by an ethanol extract of Lentinula edodes. Cancer Lett, 220, 21-8.
19. Hong WK, Sporn MB. (1997). Recent advances in chemoprevention of cancer. Science, 278, 1073-7.
20. Hsan KM, Chen CC, Shyur LF. (2010). Current research and development of chemotherapeutic agents for melanoma. Cancers, 2, 397-419.
21. Kajstura M, Halicka HD, Pryjma J, et al. (2007). Discontinuous fragmentation of nuclear DNA during apoptosis revealed by discrete "sub-G1" peaks on DNA content histograms. Cytometry, 71, 125-31.
22. Kamran MZ, Gude RP. (2012). Preclinical evaluation of the antimetastatic efficacy of Pentoxifylline on A375 human melanoma cell line. Biomed Pharmacother, 10, 6.
23. Kang N, Zhang JH, Qiu F, et al. (2010). Induction of G(2)/M phase arrest and apoptosis by oridonin in human laryngeal carcinoma cells. J Nat Prod, 73, 1058-63.
24. Kang OH, Choi JG, Lee JH, et al. (2010). Luteolin isolated from the flowers of Lonicera japonica suppresses inflammatory mediator release by blocking NF-κB and MAPKs activation pathways in HMC-1 cells. Molecules, 15, 385-98.
25. Kim MJ, Woo JS, Kwon CH, et al. (2012). Luteolin induces apoptotic cell death through AIF nuclear translocation mediated by activation of ERK and p38 in human breast cancer cell lines. Cell Biol Int, 36, 339-44.
26. Kobayashi T, Nakata T, Kuzumaki T. (2002). Effect of flavonoids on cell cycle progression in prostate cancer cells. Cancer Lett, 176, 17-23.
27. Krishnamurthy R, Maly DJ. (2010). Biochemical mechanisms of resistance to small-molecule protein kinase inhibitors. ACS Chem Biol, 5, 121-38.
28. Kuo JH, Chu YL, Yang JS, et al. (2010). Cantharidin induces apoptosis in human bladder cancer TSGH 8301 cells through mitochondria-dependent signal pathways. Int J Oncol, 37, 1243-50.
29. Lo C, Lai TY, Yang JS, et al. (2011). Gallic acid inhibits the migration and invasion of A375.S2 human melanoma cells through the inhibition of matrix metalloproteinase-2 and Ras. Melanoma Res, 21, 267-73.
30. Maioli E, Torricelli C, Fortino V, et al. (2009). Critical appraisal of the MTT assay in the presence of rottlerin and uncouplers. Biol Proced Online, 11, 227-40.
31. Middleton EJ, Kandaswami C, Theoharides TC. (2000). Effects of plant flavonoids on mammalian cells:implications for inflammation, heart disease and cancer. Pharmacol Rev, 52, 673-751.
32. Miimohammadsadegh A, Hassan M, Bardenheuer W, et al. (2006). STAT5 phosphorylation in malignant melanoma is important for survival and is mediated through SRC and JAK1 kinases. J Invest Dermatol, 126, 2272-80.
33. Miimohammadsadegh A, Mota R, Gustrau A, et al. (2007). ERK1/2 is highly phosphorylated in melanoma metastases and protects melanoma cells from cisplatin-mediated apoptosis. J Invest Dermatol, 127, 2207-15.
34. Ozgen U, Mavi A, Terzi Z, et al. (2011). Relationship between chemical structure and antioxidant activity of luteolin and its glycosides isolated from Thymus. Rec Nat Prod, 5, 12-21.
35. Pelicano H, Carney D, Huang P. (2004). ROS stress in cancer cells and therapeutic implications. Drug Resist Updat, 7, 97-110.
36. Ross JA, Kasum CM. (2002). Dietary flavonoids: bioavailability, metabolic effects, and safety. Annu Rev Nutr, 22, 19-34.
37. Seelinger G, Merfort I, Schempp CM. (2008). Anti-oxidant, antiinflammatory and anti-allergic activities of luteolin. Planta Med, 74, 1667-77.
38. Shahidi F. (1997). Natural antioxidants: An overview. In natural antioxidants, chemistry, health effects and applications. Edited by Shahidi F. Champaign, AOCS Press: 1-11.
39. Shi J, Wei L. (2007). Rho kinase in the regulation of cell death and survival. Arch Immunol Ther Exp, 55, 61-75.
40. Shi RX, Ong CN, Shen HM. (2004). Luteolin sensitizes tumor necrosis factor-alpha-induced apoptosis in human tumor cells. Oncogene, 23, 7712-21.
41. Shimada K, Fujikawa K, Yahara K, et al. (1992). Antioxidative properties of xanthin and autooxidation of soybean oil in cyclodextrin emulsion. J Agric Food Chem, 40, 945-8.
42. Soares JR, Dins TCP, Cunha AP, et al. (1997). Antioxidant activity of some extracts of Thymus zygis. Free Radic Res, 26, 469-78.
43. Ueda H, Yamazaki C, Yamazaki M. (2002). Luteolin as an anti-inflammatory and anti-allergic constituent of Perilla frutescens. Biol Pharm Bull, 25, 1197-202.
44. Voland C, Bord A, Peleraux A, et al. (2006). Repression of cell cycle-related proteins by oxaliplatin but not cisplatin in human colon cancer cells. Mol Cancer Ther, 5, 2149-57.
45. Wang HY, Quan K, Jiang YL, et al. (2010). Effect of Luteolin and its combination with chemotherapeutic drugs on cytotoxicity of cancer cells. J Zhejiang Uni Medi Sci, 39, 30-6.
46. Wang LM, Xie KP, Huo HN, et al. (2012). Luteolin inhibits proliferation induced by IGF-1 pathway dependent ERα in human breast cancer MCF-7 cells. Asian Pac J Cancer Prev, 13, 1431-7.
47. Wang Z, Tang X, Zhang Y, et al. (2012). Lobaplatin induces apoptosis and arrests cell cycle progression in a human cholangio carcinoma cell line RBE. Biomed Pharmacother, 66, 161-6.
48. Weislow OS, Kiser R, Fine DL, et al. (1989). New solubleformazan assay for HIV-1 cytopathic effects: application to high-flux screening of synthetic and natural products for AIDS-antiviral activity. J Natl Cancer Inst, 81, 577-86.
49. Xu K, Liu B, Ma Y, et al. (2009). Physicochemical properties and antioxidant activities of luteolin-phospholipid complex. Molecules, 14, 3486-93.